Navigation Links
Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy

Cytos Biotechnology reports positive results from placebo controlled phase IIa study in patients suffering from house dust mite allergy

SCHLIEREN (Zurich), Switzerland, May 15, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a multi-centre and placebo-controlled phase IIa study with different formulations of CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderate allergic rhinitis due to house dust mite allergy and assessed in a double-blind setting the safety, tolerability and exploratory efficacy of CYT003-QbG10 monotherapy, CYT003-QbG10 combined with a low dose of house dust mite allergen extract (designated CYT005-AllQbG10), allergen extract alone and placebo. Exploratory efficacy was determined by evaluating the allergic disease status of the patients before and after treatment by the conjunctival provocation test.

Both formulations of CYT003-QbG10 tested were safe and well tolerated. The table below summarizes
on the first results obtained two weeks after the last dose. A statistically significant increase in the
median allergen tolerance against baseline was observed only in the two treatment arms which
comprised QbG10 (i.e. CYT003-QbG10 monotherapy and CYT005-AllQbG10), whereas none of the
intergroup comparisons achieved statistical significance.

CYT003-QbG10
n=10
CYT005-AllQbG10
n=10
Placebo
n=10
Allergen
n=10
Increase of median
allergen tolerance
against baseline
factor of 10
factor of 10
factor of 1
factor of 10
p-value <0.05 <0.05 n.s. n.s.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology commented: “With each study we gain a deeper
understanding of the activity of QbG10 in allergic diseases. If we look at the entire data set of the
80 allergic pa
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:8/3/2015)... -- Sage Analytics ( www.sageanalytics.com ), the developers of a ... announced its sponsorship of the California Cannabis Industry Association ... of tickets are available for groups or individuals to ... enjoying an open bar, buffet dinner and hors d,oeuvres, ... at sunset. With the legislative session in ...
(Date:8/3/2015)... , August 3, 2015 ... expected to reach USD 24.7 billion by 2022, ... Research Inc. Growing prevalence of neurological and musculoskeletal ... market over the forecast period. The presence of ... cryotherapy, advancement in the technologies coupled with implementation ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... INC. (Nasdaq: VION ) today announced that ... agent Cloretazine(R) (VNP40101M) in,acute myelogenous leukemia (AML) would ... of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago,Illinois., ... blind placebo-controlled,randomized phase III study of high-dose continuous ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 3
(Date:8/3/2015)... ... 03, 2015 , ... According to an opinion piece published July 28 by the ... one pound of weight loss may not be accurate. While this system may work for ... of fat varies – based both on the individual and at what point that person ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... diseases researchers from the University of Pittsburgh School of Medicine are leading a ... prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by the ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... fitness site and the largest online retailer of nutritional supplements, has officially ... is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... TAMPA, Florida (PRWEB) , ... August 03, 2015 ... ... Association for Physician Leadership ® and Navigant Center for Healthcare Research and Policy ... nationwide. , Fifty-five percent of respondents said they agreed or strongly agreed that ...
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... VEGAS, Oct. 7 Cord Blood America, Inc. (OTC Bulletin ... ( http://www.cordblood-america.com ) focused on bringing the ... to families nationwide and internationally, said today that it has ... the third quarter of 2009. Total debt eliminated in ...
... The Ensign Group, Inc. (Nasdaq: ENSG ), announced ... skilled nursing and independent living campus, as well as ... acquisition was effective October 1, 2009. , (Logo: ... existing operational base and broaden our service offerings in ...
... LONDON and WASHINGTON, Oct. 7 Tranziger Limited announced ... team to advise and assess companies in the life ... realise and optimise value from their portfolios in these ... UK and has offices in Washington, DC and Edinburgh. ...
... ... Flexible Hypervisor Technologies Managed by Unified Set of Automation Tools Enable Profitable Cloud Services ... ... leader, Parallels , today announced enhancements to its server virtualization product portfolio to ...
... ... security landscape, endpoint security, and IT GRC with industry leaders , ... Scottsdale, AZ (PRWEB) October 7, 2009 -- As cybercrime ... organizations are faced with the challenge of staying ahead of these threats. To enable ...
... ... cancer research and support foundation. , ... Hampton Roads, Va. (PRWEB) October 7, 2009--October is breast cancer awareness month. Customer Magnetism, ... of funds from all new contracts signed and received during this month toward breast cancer ...
Cached Medicine News:Health News:Cord Blood America Announces Debt Reduction Tally: $8.7 Million in 2009; $3.7 Million in Third Quarter 2Health News:The Ensign Group Acquires Dallas Skilled Nursing Campus and Hospice Business 2Health News:The Ensign Group Acquires Dallas Skilled Nursing Campus and Hospice Business 3Health News:Tranziger Announces Formation of Global Advisory & Development Team 2Health News:Tranziger Announces Formation of Global Advisory & Development Team 3Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 2Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 3Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 4Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 5Health News:Lumension Launches New Optimal IT Security Videocast Series 2Health News:Lumension Launches New Optimal IT Security Videocast Series 3Health News:Customer Magnetism Donates Funds In Support Of Breast Cancer Research 2Health News:Customer Magnetism Donates Funds In Support Of Breast Cancer Research 3
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: